Information Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
PLoS One. 2022 Aug 31;17(8):e0273691. doi: 10.1371/journal.pone.0273691. eCollection 2022.
COVID-19 is spreading rapidly worldwide, and the population is generally susceptible to SARS-CoV-2, especially those with cancer. Hence, our study aims to design a protocol for a systematic review and meta-analysis of the clinical characteristics and prognoses of lung cancer patients with COVID-19.
The protocol is prepared following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The literature will be searched in Embase, Pubmed, the Cochrane Library, LitCovid, and CNKI for potentially eligible articles. The quality of the articles will be used in the Newcastle-Ottawa Quality Assessment Scale (NOS) and Cochrane Handbook for Systematic Reviews of Interventions. Statistical analysis will be performed through RevMan 5 software. This review protocol has been registered in PROSPERO (CRD42022306866).
To clarify whether COVID-19 affects the clinical symptoms and prognoses of lung cancer patients. Further study is needed to establish the best evidence-based for the management of lung cancer patients with COVID-19.
The definitive conclusion will be important to physicians effectively manage lung cancer patients with COVID-19.
COVID-19 在全球范围内迅速传播，人群普遍易感染 SARS-CoV-2，尤其是癌症患者。因此，我们的研究旨在设计一项针对 COVID-19 肺癌患者临床特征和预后的系统评价和荟萃分析的方案。
该方案遵循系统评价和荟萃分析的首选报告项目（PRISMA）指南制定。将在 Embase、Pubmed、Cochrane 图书馆、LitCovid 和 CNKI 中搜索可能符合条件的文章。文章的质量将使用纽卡斯尔-渥太华质量评估量表（NOS）和 Cochrane 干预系统评价手册进行评估。统计分析将通过 RevMan 5 软件进行。本综述方案已在 PROSPERO（CRD42022306866）中注册。
明确 COVID-19 是否影响肺癌患者的临床症状和预后。需要进一步的研究来确定 COVID-19 肺癌患者管理的最佳循证依据。
明确 COVID-19 是否影响肺癌患者的临床症状和预后。需要进一步的研究来确定 COVID-19 肺癌患者管理的最佳循证依据。明确 COVID-19 是否影响肺癌患者的临床症状和预后。需要进一步的研究来确定 COVID-19 肺癌患者管理的最佳循证依据。
明确 COVID-19 是否影响肺癌患者的临床症状和预后。需要进一步的研究来确定 COVID-19 肺癌患者管理的最佳循证依据。
最终结论对医生有效管理 COVID-19 肺癌患者至关重要。
